Welcome to our dedicated page for Stimcell Energetics SEC filings (Ticker: STME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with electrophysiology terms and R&D burn rates can feel like navigating a lab notebook. StimCell Energetics’ disclosures run deep—detailing microcurrent eBalance® trials, partnerships, and patent updates that directly affect its valuation. If you’ve ever scrolled hundreds of pages hunting for a single clinical milestone, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries turn each StimCell Energetics annual report 10-K into plain-English takeaways, flagging exactly where management discusses device efficacy and regulatory pathways. Need the numbers now? Real-time alerts deliver every StimCell Energetics quarterly earnings report 10-Q filing, plus Form 4 insider transactions the moment executives trade shares. You’ll also find:
- "StimCell Energetics insider trading Form 4 transactions" with trend graphs
- "StimCell Energetics 8-K material events explained" in concise briefs
- Proxy statements that clarify executive compensation and option grants
Whether you’re monitoring cash runway, comparing R&D spend quarter over quarter, or tracking when leadership buys stock, our platform ties filing sections to the biotech factors that move STME shares. Use AI discussion prompts like “understanding StimCell Energetics SEC documents with AI” to dig deeper, or skim the highlighted tables for ATP-boosting device sales. From "StimCell Energetics earnings report filing analysis" to "StimCell Energetics executive stock transactions Form 4," every disclosure is organized, summarized, and searchable—so you can make informed decisions without wading through technical jargon.
Stimcell Energetics Inc. (STME) reported a wider quarterly loss and tight liquidity in its Q1 FY2026 (three months ended August 31, 2025). Net loss was $265,602 versus $66,919 a year ago as operating expenses rose to $252,354 (from $59,636), driven by higher general and administrative costs and renewed R&D. The company ended the quarter with $6,437 in cash and a working capital deficit of $1,393,949. Total liabilities were $1,410,336 and stockholders’ deficit was $(1,393,949).
Management disclosed substantial doubt about going concern. Operations used $108,142 of cash; financing provided $100,000 from a related-party credit line at 10% per annum. The company issued 375,000 shares for services valued at $120,000 during the quarter and a subsequent 125,000 shares valued at $33,750. R&D was $57,309, tied to the eBalance redesign with ADM Tronics. Internal controls over disclosure were assessed as not effective due to lack of segregation of duties. Common shares outstanding were 20,641,272 as of October 14, 2025.
FAQ
What is the current stock price of Stimcell Energetics (STME)?
What is the market cap of Stimcell Energetics (STME)?
